Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

Trial Profile

Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs GALE 301 (Primary) ; GALE 302 (Primary)
  • Indications Breast cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Galena Biopharma
  • Most Recent Events

    • 09 Mar 2017 Status changed from active, no longer recruiting to completed, as reported in a Galena Biopharma media release.
    • 12 Dec 2016 According to a Galena Biopharma media release, data from this study were presented as a poster at the San Antonio Breast Cancer Symposium (SABCS).
    • 12 Dec 2016 Results published in the Galena Biopharma Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top